Aims: Reflux symptoms are highly prevalent and non-specific; hence, in the absence of alarm symptoms, endoscopy referral decisions are challenging. This study evaluated whether a non-endoscopic Cytosponge could detect benign oesophageal pathologies and thus have future potential in triaging patients with persistent symptoms. Methods and results: Two complementary cohorts were recruited: (i) patients with reflux symptoms and no prior endoscopy (n = 409), and (ii) patients with reflux symptoms referred for endoscopy (n = 411). All patients were investigated using the Cytosponge and endoscopy. Significant epithelial inflammation was present in 130 (16%) Cytosponge samples, 32 of which had ulcer slough. Candida and significant inflammation was detected in a further 22 (2.3%) cases; epithelial infiltration with >15 eosinophils/high-power field reflecting possible eosinophilic oesophagitis (EOE) in five (0.6%); and viral inclusions suggestive of herpes oesophagitis in one (0.1%). No significant pathology was detected in the majority, 662 (81%), of Cytosponge samples. Cytosponge and endoscopy findings were in agreement in 574 (70%) cases, in 165 (67%) of the discordant cases one investigation showed mild inflammation while the other was negative, with an additional 22 (8.9%) differing on the extent of inflammation. Eighteen cases with severe inflammation, six with candida and two with EOE were detected only at endoscopy, while 18 with candida and significant inflammation, 13 with ulcer slough, one probable EOE and one viral oesophagitis were identified on the Cytosponge only. Conclusions: The Cytosponge detects a range of benign oesophageal pathologies, and therefore has potential clinical utility in the triaging of patients with troublesome reflux symptoms. This warrants further investigation.
Introduction
Gastro-oesophageal reflux symptoms are highly prevalent in the westernized world, affecting 10-44% of the general population, and continue to increase in incidence. 1 They are the most common gastrointestinal symptoms resulting in physician office visits in the United States and accrue the highest annual costs. 2, 3 US and UK guidelines suggest that patients reporting classical symptoms of dyspepsia, heartburn and/or regurgitation should be managed as presumptive gastrointestinal reflux disease (GORD) with advice on life-style modifications, reviewing any contributory drugs, and a trial of proton pump inhibitors (PPI). 4, 5 If symptoms return on initial discontinuation of PPI therapy, it is recommended to restart the drug and to tailor the dosing schedule to maximize symptom control. 4, 5 In the majority of cases this would be expected to control symptoms fully; however, 17-32% of patients in a primary-care setting remain symptomatic. 6 Currently it is recommended that this group requires further optimization of medical therapy followed by a referral to specialist services with consideration of an upper oesophago-gastroduodenoscopy (OGD) to identify patients with erosive oesophagitis, Barrett's oesophagus or other benign diagnosis requiring further management and/or disease surveillance. 4, 5, 7, 8 Erosive oesophagitis is the most common positive OGD finding in patients with reflux symptoms, 9 identified in 12-34%. 10, 11 However, reflux symptoms may be secondary to alternative pathologies which are non-responsive to PPIs and therefore require alternative management. 12 The most prevalent is candida oesophagitis, identified in 2.3-3.8% of all OGDs. [13] [14] [15] When symptomatic, it presents predominantly with reflux symptoms, 14 and requires treatment with antifungal medication. Eosinophilic oesophagitis (EOE) is a condition of uncertain aetiology which is increasing in incidence. 16 Acute dysphagia is the classical presentation; 17 however, EOE is identified in 1% of patients who are investigated for reflux symptoms and requires management with a trial of PPI, topical or systemic steroids and/or dietary elimination. 18, 19 It is estimated, however, that at least two-thirds of OGDs in patients with reflux symptoms will not reveal any diagnostic pathology. An OGD requires patients to be referred to secondary care, to undergo a relatively invasive procedure and has associated costs of approximately $685 or £400 per outpatient investigation. 2, 20 Previous studies have demonstrated a non-endoscopic cell sampling method, the Cytosponge, to be a safe and well-tolerated method to sample the oesophageal lining which can be undertaken in a primary-care setting by nurse practitioners. [21] [22] [23] The device yields a combination of single cells and microbiopsies which quantitatively exceeds that achieved by a biopsy ( Figure S1 ). Compared to an OGD, it offers a cost-effective method to diagnose Barrett's oesophagus in high-risk patients 24 with a high sensitivity and specificity when combined with TFF3 immunohistochemistry, [23] [24] [25] and has also demonstrated utility in monitoring disease activity in patients with EOE. 26 The aim of this study was to explore, in symptomatic patients with no prior oesophageal diagnosis, the ability of the Cytosponge to detect benign oesophageal pathology aside from Barrett's oesophagus.
Methods

S T U D Y C O H O R T
The study group comprised two complementary cohorts, patients enrolled into the Barrett's oEsophagus Screening Trial (BEST) study 21 and the control group from the BEST2 study. 23 To summarize, the BEST cohort was identified from a primary-care setting, and had received acid-suppression medication for at least 3 consecutive months in the 5 years prior to being enrolled into the study. These patients were not considered to require an OGD by their primary care physician. Patients were excluded if they were known to have Barrett's oesophagus or if they had had an OGD in the 12 months prior to enrolment. The BEST2 control group were patients who had been referred for an OGD to investigate dyspepsia and/or reflux symptoms refractory to medical therapy. Patients with a prior diagnosis of Barrett's oesophagus were excluded.
The UK Medical Health Regulatory Agency issued a letter of no objection for the use of the Cytosponge (Medical Research Council, London, UK) in both studies. The BEST and BEST2 studies were approved by The Cytosponge was administered by a research nurse and following retrieval was stored at 4°C in SurePath preservative (TriPath Imaging, Burlington, NC, USA) before being transferred to the laboratory for processing to paraffin blocks. 21, 23 One haematoxylin and eosin (H&E)-stained slide was generated per sample and all cases were reviewed by at least two independent observers (M.O'D. and P.L.S.), one of whom (M.O'D.) is a specialist cytopathologist and gastrointestinal pathologist. Any features suggestive of benign pathology were recorded. In a subset of cases (n = 7) where both candida and significant inflammation was present on the H&E-stained slide, a periodic acid-Schiff (PAS) stain was undertaken to improve diagnostic certainty.
Patients then underwent an OGD with biopsies taken where clinically indicated, according to usual clinical care. All the endoscopists in the study were consultant-level, with a particular interest in oesophageal disease, and followed a study protocol. Endoscopic findings were categorized based on the endoscopy report and supplemented by histopathology findings when biopsies were undertaken. Mild oesophagitis was defined as Los Angeles oesophagitis grades A or B, or inflammation identified only on a biopsy, while severe oesophagitis was defined as the presence of Los Angeles grades C or D erosions 4 and/ or ulceration. This was an observational study, and no therapy was initiated as a result of Cytosponge findings; patient management was adjusted as per current recommendations based on the endoscopic findings.
The sensitivity and specificity of the Cytosponge as a screening tool for Barrett's oesophagus and associated dysplasia has been reported previously; 23 therefore, cases where Barrett's oesophagus was identified using the Cytosponge and/or OGD were excluded (n = 94), unless an additional significant benign pathology was also present (n = 9).
S T A T I S T I C A L A N A L Y S I S
Statistics for continuous variables were expressed as medians and interquartile ranges. The Mann-Whitney U-test was used to compare continuous variables between groups, and a v 2 test was used to compare counts between categorical variables.
Results
A total of 820 patients met the inclusion criteria for the study, 409 patients from BEST and 411 from BEST2. The demographic data are summarized in Table 1 . The BEST group reported less well-controlled symptoms compared with the BEST2 cohort, were older and more likely to have a high body mass index (BMI) and/or waist:hip ratio.
C Y T O S P O N G E F I N D I N G S
A range of benign oesophageal pathologies were identified using the Cytosponge; 662 of 820 (81%) Cytosponge samples were considered to be within normal limits ( Figure 1A,B) , including occasional samples containing Aspergillus species, a recognized commensal in tonsillar tissue ( Figure 1C,D) . In the majority of cases only occasional acute and chronic inflammatory cells were present, usually separate from epithelial fragments, and therefore were deemed not to be clinically significant. However, in a subgroup of patients, 98 of 820 (12%), abundant acute and chronic inflammatory cells were seen to permeate the epithelial fragments ( Figure 1E,F) or to be present in dense clusters separate from the epithelial fragments.
In both situations, this was felt to represent clinically significant inflammation. In 32 (3.9%) additional cases, dense aggregates of predominantly acute inflammatory cells were observed with abundant associated fibrin ( Figure 1G,H) , and interpreted as sampling from the surface of an ulcer.
Fungal spores and/or pseudo-hyphae with an appearance consistent with Candida species were identified in 35 of 820 (4.3%) cases. As candida is a known commensal within the oropharynx, its presence was only judged to be potentially pathogenic in 22 of 820 (2.7%) patients where significant inflammation was also present (Figure 1I,J) .
In five of 820 (0.6%) cases eosinophils were seen to infiltrate between epithelial cells with a density of >15 eosinophils per high-power field, and in some cases with micro-abscess formation ( Figure 1M,N) . Therefore, these samples met multiple histological criteria used for the diagnosis of EOE on biopsy 18 and were designated possible EOE. Viral nuclear inclusions, representing herpes oesophagitis, were present in a single case ( Figure 1O ,P).
E N D O S C O P I C F I N D I N G S A N D C O M P A R I S O N W I T H T H E C Y T O S P O N G E
In the majority of cases, 638 of 820 (78%), no significant pathology was identified at endoscopy. Oesophagitis was the most common pathology and present in 166 of 820 (20%) cases, the majority of which, 101 of 166 (61%), were grade A oesophagitis with only 30 of 166 (18%) having severe oesophagitis. Candida oesophagitis and EOE were identified in 10 of 820 (1.2%) and six of 820 (0.7%) cases, respectively.
There was agreement between the findings on endoscopy and Cytosponge in 596 of 820 (73%) cases, with both showing no significant pathology in 541 of 820 (66%) ( Table 2 ). In some cases, one of the investigations led to a diagnosis which was not corroborated by the other test. In 121 of 820 (15%) cases the Cytosponge was negative when a pathology was identified at endoscopy (Table 2 ). This was predominantly mild inflammation, 97 of 121 (80%), as well as 18 cases (15%) with severe oesophagitis and six cases (5.0%) of Candida oesophagitis. In 97 of 820 (11%) cases the endoscopy was negative when the Cytosponge identified pathology ( Table 2 ). The missed diagnoses at endoscopy were significant inflammation or ulceration in 81 of 97 (84%) patients, candida with significant accompanying inflammation in 15 of 97 (15%) and a single case with viral inclusions suggestive of herpes oesophagitis. In 80 of 97 (82%) cases where pathology was noted on the Cytosponge but not at endoscopy, no biopsy had been taken at endoscopy as it was not felt to be indicated clinically. In three cases mild atypia was noted on the Cytosponge sample; however, as significant inflammation related to reflux, candida or EOE was also present, the significance is unclear and this may represent reactive changes. No squamous dysplasia was seen in the single case where a biopsy was also taken.
In a further six of 820 (0.7%) cases, there was disagreement between the OGD and Cytosponge findings. In two cases the Cytosponge detected mild inflammation while the OGD suggested that this was due to EOE; and in four cases the OGD found mild oesophagitis while the Cytosponge examination suggested that this was secondary to Candida oesophagitis (three cases) and EOE (one case).
Discussion
This study has demonstrated the ability of a minimally invasive sampling device, the Cytosponge, to detect a broad range of benign oesophageal pathologies. This is a preliminary study; however, it suggests that this test has future potential for triaging and possibly even guiding the management of patients with reflux symptoms, and warrants further research to explore the clinical utility of such a strategy.
The Cytosponge can be administered by a nurse practitioner in a primary-care or specialist clinic setting within a 15-min appointment. From the patient's Table 2 . Comparison of the findings on oesophago-gastroduodenoscopy (OGD) and using the Cytosponge. Cases with a shared diagnosis are shaded in blue, those where only the Cytosponge detected the dominant pathology are shaded green, and those when the main pathology was only identified by OGD are shaded red perspective this may be more convenient than an outpatient endoscopy, and previous studies have shown that most patients do not find the Cytosponge to be an unpleasant or anxiety-provoking investigation, preferring it to endoscopy. 21, 23 From a healtheconomics perspective, the Cytosponge is anticipated to be cheaper to deliver than an endoscopy, mainly because it does not require specialist services or equipment.
In the majority of cases, 66%, both the Cytosponge and endoscopy showed no significant pathology. Alternative diagnoses to GORD were identified in 36 (4.4%) patients when the findings from the OGD and Cytosponge are combined, consistent with previous findings. 14, 15, 19 The main diagnosis was candida with significant associated inflammation, which was detected more than twice as frequently using the Cytosponge compared to an OGD. A PAS stain was also shown to be effective in highlighting Candida species on Cytosponge samples, and could be used selectively in future studies to increase the sensitivity of the Cytosponge to detect candida in cases with severe inflammation and ulceration. The clinical significance of candida identified using the Cytosponge needs further study; however, such patients could be treated by a short course of antifungal therapy, which is well tolerated, and it is likely that such cases would not have symptom control with PPIs alone.
The majority of patients with EOE present with dysphagia, and so would be referred directly for endoscopy; 17 however, a subset have predominantly reflux-type symptoms and the Cytosponge detected five cases of probable EOE in our study groups. Diagnostic criteria applied to biopsies, the presence of >15 eosinophils per high-power field infiltrating the epithelium and/or the presence of eosinophilic microabscesses, 18 are equally applicable to the Cytosponge samples due to the microbiopsies that are obtained. A recent small study of patients with known EOE found that the Cytosponge had a sensitivity of 85% for identifying active disease. 26 EOE is known to have a patchy distribution and may not be visible endoscopically. 12 A major advantage of the Cytosponge is that it samples the entire length of the oesophagus and so is less susceptible to sampling errors. However, eosinophils are seen frequently in biopsies from the distal oesophagus in reflux oesophagitis; hence, to diagnose EOE at endoscopy, eosinophils should be present in biopsies taken from both the distal and proximal oesophagus. 18 Therefore, patients suspected of having EOE based on the Cytosponge findings would require endoscopic confirmation prior to starting treatment.
The majority of missed diagnoses for both the sponge and endoscopy related to oesophagitis and/or ulceration. This disagreement is not unique to this setting, as the scoring of oesophagitis and ulceration at endoscopy is known to have limited interobserver agreement, j score 0.40-0.65. 27, 28 Furthermore, the majority of medical adjustments to acid-suppression therapy are guided by patient symptoms, not by endoscopic findings, 4 as patients can report severe symptoms in the absence of oesophagitis on endoscopy. 27 A major challenge in the broader interpretation of this study is calculating accurately the specificity and sensitivity of the Cytosponge investigation. 29 The endoscopy protocol reflected standard clinical practice, hence in the majority of cases where pathology was identified on the Cytosponge but not macroscopically at endoscopy a biopsy was not taken, so it is not possible to confirm or refute the Cytosponge findings microscopically. Furthermore, biopsies were not taken as standard to confirm the macroscopic impression of inflammation, therefore 'false-negative' Cytosponge findings cannot be confirmed, particularly as concordance between endoscopists is known to be low for mild oesophagitis. 27, 28 Therefore, given that the ability of the Cytosponge to detect benign oesophageal pathologies has been established here, future studies now need to be undertaken to establish the sensitivity and specificity of this investigation accurately compared to endoscopy and hence its potential clinical utility. For example, the Cytosponge may offer a means to triage patients with troublesome reflux symptoms, without alarm features, away from first-line endoscopic investigation. Patients in whom the Cytosponge demonstrates no significant pathology, epithelial inflammation without ulceration or candida with associated inflammation, representing 95% of our cohort, could continue to be managed in primary care with adjustment of acid suppression therapy or antifungal medication as appropriate. While those with evidence of ulceration, possible EOE or viral oesophagitis on the Cytosponge, in addition to those with troublesome, persistent or unexplained symptoms following a negative Cytosponge investigation, would be referred for a diagnostic or follow-up endoscopy. An OGD would remain the investigation of choice for all patients presenting with alarm symptoms, or dyspepsia as the Cytosponge is not intended to be used to detect gastric pathology.
To conclude, this research demonstrates the ability of the Cytosponge to detect benign oesophageal pathologies. Prospective studies are now required to explore its potential as a triage tool in patients with troublesome reflux symptoms.
